1. World Health Organization. Sexually Transmitted Infections (STIs), viewed 20 December 2022, https://www.who.int/news-room/fact-sheets/detail/sexually-transmitted-infections-(stis)
2. Global Health Sector Strategy on Sexually Transmitted Infections, 2016-2021. Towards Ending STIs. World Health Organization, 2016, Geneva.
3. Kraus SJ, 1979, Culture Methods for Neisseria gonorrhoea. Arch Androl, 3: 343–349.
4. Peng L, Chen JL, Wang D, 2020, Progress and Perspectives in Point of Care Testing for Urogenital Chlamydia trachomatis Infection: A Review. Med Sci Monit, 26: e920873.
5. Meyer T, Buder S, 2020, The Laboratory Diagnosis of Neisseria gonorrhoeae: Current Testing and Future Demands. Pathogens, 9: 91.
6. Gaydos CA, Klausner JD, Pai NP, et al., 2017, Rapid and Point-of-Care Tests for the Diagnosis of Trichomonas vaginalis in Women and Men. Sex Transm Infect, 93: S31–S35.
7. Herring A, Ballard R, Mabey D, et al., 2006, Evaluation of Rapid Diagnostic Tests: Chlamydia and Gonorrhoea. Nat Rev Microbiol, 4: S41–S48.
8. Sena AC, White BL, Sparling PF, 2010, Novel Treponema pallidum Serologic Tests: A Paradigm Shift in Syphilis Screening for the 21st Century. Clin Infect Dis, 51: 700–708.
9. Nsuami M, 2003, Recommendations for Screening High School Students for Chlamydia and Gonorrhea in San Francisco. Sex Transm Dis, 30: 367.
10. Ford CA, Viadro CI, Miller WC, 2004, Testing for Chlamydial and Gonorrheal Infections Outside of Clinic Settings: A Summary of the Literature. Sex Transm Dis, 31: 38–51.
11. Dumkow LE, Worden LJ, Rao SN, 2021, Syndromic Diagnostic Testing: A New Way to Approach Patient Care in the Treatment of Infectious Diseases. J Antimicrob Chemother, 76: iii4–iii11.
12. Ramanan P, Bryson AL, Binnicker MJ, et al., 2018, Syndromic Panel-Based Testing in Clinical Microbiology. Clin Microbiol Rev, 31: e00024-17.
13. Popowitch EB, O’Neill SS, Miller MB, 2013, Comparison of the Biofire FilmArray RP, Genmark eSensor RVP, Luminex xTAG RVPv1, and Luminex xTAG RVP Fast Multiplex Assays for Detection of Respiratory Viruses. J Clin Microbiol, 51: 1528–1533.
14. Ward C, Stocker K, Begum J, et al., 2015, Performance Evaluation of the Verigene® (Nanosphere) and FilmArray® (BioFire®) Molecular Assays for Identification of Causative Organisms in Bacterial Bloodstream Infections. Eur J Clin Microbiol Infect Dis, 34: 487–496.
15. Guidelines for the Management of Symptomatic Sexually Transmitted Infections. World Health Organization, 2021, Geneva.
16. Nelson K, Joseph A, Wiesneth R, et al., 2019, P058 Design and Performance of the Alinity m STI Assay for the Detection of CT, NG, TV, and MG. Sex Transm Infect, 95: A103.
17. Hristov A, Galindo L, Gentil L, et al., 2021, P268 Clinical Performance Assessment of the Alinity m STI Assay. Sex Transm Infect, 97: A129–A130.
18. Huh HJ, Ki CS, Yun SA, et al., 2019, Comparison between DiaPlexQ™ STI6 and GeneFinder™ STD I/STD II Multiplex Real-Time PCR Kits in the Detection of Six Sexually Transmitted Disease Pathogens. J Clin Lab Anal, 33: e22703.
19. Park HJ, Kim YT, Moon JY, et al., 2021, Trend Analysis of the Profiles of 12 Sexually Transmitted Disease Pathogens in the Republic of Korea in 2019. Inquiry, 58: 469580211065684.
20. CDC, 2011, Sexually Transmitted Diseases Treatment Guidelines, 2010. Ann Emerg Med, 58: 67–68.
21. Xie TA, Liu YL, Meng RC, et al., 2020, Evaluation of the Diagnostic Efficacy of Xpert CT/NG for Chlamydia trachomatis and Neisseria gonorrhoeae. Biomed Res Int, 2020: 2892734.
22. Dukers-Muijrers NHTM, Schachter J, van Liere GAFS, et al., 2015, What is Needed to Guide Testing for Anorectal and Pharyngeal Chlamydia trachomatis and Neisseria gonorrhoeae in Women and Men? Evidence and Opinion. BMC Infect Dis, 15: 533.
23. Cristillo AD, Bristow CC, Peeling R, et al., 2017, Point-of-Care Sexually Transmitted Infection Diagnostics: Proceedings of the STAR Sexually Transmitted Infection-Clinical Trial Group Programmatic Meeting. Sex Transm Dis, 44: 211–218.
24. de Cortina SH, Bristow CC, Davey DJ, et al., 2016, A Systematic Review of Point of Care Testing for Chlamydia trachomatis, Neisseria gonorrhoeae, and Trichomonas vaginalis. Infect Dis Obstet Gynecol, 2016: 4386127.
25. Tucker JD, Bien CH, Peeling RW, 2013, Point-of-Care Testing for Sexually Transmitted Infections: Recent Advances and Implications for Disease Control. Curr Opin Infect Dis, 26: 73–79.
26. Barrow RY, Ahmed F, Bolan GA, et al., 2020, Recommendations for Providing Quality Sexually Transmitted Diseases Clinical Services, 2020. MMWR Recomm Rep, 68: 1–20.
27. Peeling RW, Holmes KK, Mabey D, et al., 2006, Rapid Tests for Sexually Transmitted Infections (STIs): The Way Forward. Sex Transm Infect, 82 Suppl 5: v1–v6.
28. Hsieh YH, Gaydos CA, Hogan MT, et al., 2011, What Qualities are Most Important to Making a Point of Care Test Desirable for Clinicians and Others Offering Sexually Transmitted Infection Testing? PLoS One, 6: e19263.
29. Cosentino LA, Danby CS, Rabe LK, et al., 2017, Use of Nucleic Acid Amplification Testing for Diagnosis of Extragenital Sexually Transmitted Infections. J Clin Microbiol, 55: 2801–2807.
30. Gettinger J, Van Wagoner N, Daniels B, et al., 2020, Patients are Willing to Wait for Rapid Sexually Transmitted Infection Results in a University Student Health Clinic. Sex Transm Dis, 47: 67–69.
31. Van Der Pol B, Gaydos CA, 2021, A Profile of the Binx Health io® Molecular Point-of-Care Test for Chlamydia and Gonorrhea in Women and Men. Expert Rev Mol Diagn, 21: 861–868.
32. Van Der Pol B, Taylor SN, Mena L, et al., 2020, Evaluation of the Performance of a Point-of-Care Test for Chlamydia and Gonorrhea. JAMA Netw Open, 3: e204819.
33. Antibiotic Resistance Threats in the United States, 2019, United States Centers for Disease Control and Prevention, 2019, Atlanta.
34. Lewis DA, 2014, Global Resistance of Neisseria gonorrhoeae: When Theory Becomes Reality. Curr Opin Infect Dis, 27: 62–67.
35. Wi T, Lahra MM, Ndowa F, et al., 2017, Antimicrobial Resistance in Neisseria gonorrhoeae: Global Surveillance and a Call for International Collaborative Action. PLoS Med, 14: e1002344.
36. CDC, 2007, Update to CDC’s Sexually Transmitted Diseases Treatment Guidelines, 2006: Fluoroquinolones No Longer Recommended for Treatment of Gonococcal Infections. MMWR Morb Mortal Wkly Rep, 56: 332–336.
37. Lee H, Suh YH, Lee S, et al., 2019, Emergence and Spread of Cephalosporin-Resistant Neisseria gonorrhoeae with Mosaic penA Alleles, South Korea, 2012–2017. Emerg Infect Dis, 25: 416–424.
38. Gernert KM, Seby S, Schmerer MW, et al., 2020, Azithromycin Susceptibility of Neisseria gonorrhoeae in the USA in 2017: A Genomic Analysis Of Surveillance Data. Lancet Microbe, 1: e154–e164.
39. Clegg A, Passey M, Yoannes M, et al., 1997, High Rates of Genital Mycoplasma Infection in the Highlands of Papua New Guinea Determined Both by Culture and by a Commercial Detection Kit. J Clin Microbiol, 35: 197–200.
40. Waites KB, Katz B, Schelonka RL, 2005, Mycoplasmas and Ureaplasmas as Neonatal Pathogens. Clin Microbiol Rev, 18: 757–789.
41. Murtha AP, Edwards JM, 2014, The Role of Mycoplasma and Ureaplasma in Adverse Pregnancy Outcomes. Obstet Gynecol Clin, 41: 615–627.
42. Song T, Ye A, Xie X, et al., 2014, Epidemiological Investigation and Antimicrobial Susceptibility Analysis of Ureaplasma species and Mycoplasma hominis in Outpatients with Genital Manifestations. J Clin Pathol, 67: 817–820.
43. Valentine-King MA, Brown MB, 2017, Antibacterial Resistance in Ureaplasma species and Mycoplasma hominis Isolates from Urine Cultures in College-Aged Females. Antimicrob Agents Chemother, 61: e01104-17.
44. Lis R, Rowhani-Rahbar A, Manhart LE, 2015, Mycoplasma genitalium Infection and Female Reproductive Tract Disease: A Meta-Analysis. Clin Infect Dis, 61: 418–426.
45. Taylor-Robinson D, Jensen JS, 2011, Mycoplasma genitalium: From Chrysalis to Multicolored Butterfly. Clin Microbiol Rev, 24: 498–514.
46. Jensen JS, Cusini M, Gomberg M, et al., 2016, 2016 European Guideline on Mycoplasma genitalium Infections. J Eur Acad Dermatol Venereol, 30: 1650–1656.
47. Korean Guideline for Sexually Transmitted Infection. 2nd ed. Korean Centers for Disease Control and Prevention, 2016, Seoul.
48. Jensen JS. Protocol for the Detection of Mycoplasma genitalium by PCR from Clinical Specimens and Subsequent Detection of Macrolide Resistance-Mediating Mutations in Region V of the 23S rRNA gene. In: MacKenzie C, Henrich B (eds). Diagnosis of Sexually Transmitted Diseases. 2012, Humana Press, Totowa, 129–139.
49. Tagg KA, Jeoffreys NJ, Couldwell DL, et al., 2013, Fluoroquinolone and Macrolide Resistance-Associated Mutations in Mycoplasma genitalium. J Clin Microbiol, 51: 2245–2249.
50. Hadad R, Cole MJ, Ebeyan S, et al., 2021, Evaluation of the SpeeDx ResistancePlus® GC and SpeeDx GC 23S 2611 (Beta) Molecular Assays for Prediction of Antimicrobial Resistance/Susceptibility to Ciprofloxacin and Azithromycin in Neisseria gonorrhoeae. J Antimicrob Chemother, 76: 84–90.
51. Gardette M, Hénin N, Roy CL, et al., 2022, Clinical Performance of Three Commercial Molecular Diagnostic Assays for the Detection of Fluoroquinolone Resistance-Associated Mutations in Mycoplasma genitalium. J Clin Microbiol, 60: e0113522.
52. Sweeney EL, Lowry K, Ebeyan S, et al., 2020, Evaluation of the SpeeDx MG parC (Beta) PCR Assay for Rapid Detection of Mycoplasma genitalium Quinolone Resistance-Associated Mutations. J Clin Microbiol, 58: e01432-20.
53. Shipitsyna E, Khusnutdinova T, Budilovskaya O, et al., 2022, Performance of the First Commercial Dual Resistance Assay, AmpliSens Mycoplasma genitalium-ML/FQ-Resist-FL, for Detection of Potential Macrolide and Quinolone Resistance-Associated Mutations and Prevalence of M. genitalium Resistance Mutations in St. Petersburg, Russia. Sex Transm Infect, 99: 191–194.